Sorafenib
- PDF / 170,177 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 71 Downloads / 151 Views
1 S
Leucocytoclastic vasculitis: case report A 77-year-old man developed leucocytoclastic vasculitis (LCV) during treatment with sorafenib for metastatic hepatocellular carcinoma (HCC). The man, who had metastatic HCC, started receiving treatment with sorafenib 400mg twice daily [route not stated] in June 2017. Additionally, he was receiving various concomitant medications. Twenty days after the initiation of sorafenib, he developed fever, which lasted for 6 days before he observed painful skin lesions when he was admitted to the emergency room. Clinical examination of the lower extremities showed non-blanchable, well-defined palpable erythematous papules. Dorsum of the right foot contained a patch with a mild haemorrhagic necrotic center enclosed by violaceous to brownish borders. Laboratory investigations revealed normal WBC, elevated neutrophils, mild normocytic anaemia and increased CRP. Skin biopsy of the lesion on the left leg revealed perivascular inflammatory infiltrate in papillary dermis and normal epidermis. Leucocytoclastic foci were observed in addition to extravasated erythrocytes in surrounding dermis. Based on these findings and clinical presentation, he was diagnosed with LCV. The man was treated with unspecified glucocorticoid therapy upon admission. Additionally, he was treated with ciprofloxacin and clindamycin. His general condition was good and fever present only on the first day of admission. The rash developed only in the lower extremities and had not spread over other parts of the body. His treatment with sorafenib was discontinued for 4 weeks. During this time, the glucocorticoid therapy was tapered till the full cessation. Within the first 2 days following the initiation of steroids, the majority of lesions resolved and 10 days later no more lesions were observed. After the full recovery, his treatment with sorafenib continued at the same dose. The HCC progressed 9 months later. During this period, no more episodes of skin eruption were noted. Prejac J, et al. Leukocytoclastic vasculitis associated with sorafenib treatment for hepatocellular carcinoma. Anti-Cancer Drugs 31: 76-79, No. 1, Jan 2020. Available from: 803514461 URL: http://doi.org/10.1097/CAD.0000000000000840
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
